A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Part of paid clinical trials in Boulder, Colorado.

Sponsor
Alkermes, Inc.
Study ID
NCT07502443
Phase
PHASE3
Status
Recruiting

Conditions

  • Narcolepsy Type 2

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • ALKS 2680 Dose 1 — DRUG
    Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
  • ALKS 2680 Dose 2 — DRUG
    Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
  • ALKS 2680 Dose 3 — DRUG
    Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
  • Placebo — DRUG
    Participants will receive placebo tablets, daily, orally for 12 weeks

Study Details

The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.

Key Dates

Start date
Apr 22, 2026
Status verified
Jun 2026
Primary completion
May 31, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
176 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ALKS 2680 Dose 1
  • Experimental: ALKS 2680 Dose 2
  • Experimental: ALKS 2680 Dose 3
  • Placebo Comparator: Placebo

Primary Outcome Measure

Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level [ Time Frame: Baseline to Week 12 ]

Central Contacts

Locations (13)

FacilityCityStateZIPSite coordinators
Alkermes Investigational SiteBoulderColorado80301-
Alkermes Investigational SiteBrandonFlorida33511-
Alkermes Investigational SiteMaimiFlorida33176-
Alkermes Investigational SiteWinter ParkFlorida32789-
Alkermes Investigational SiteMaconGeorgia31210-
Alkermes Investigational SiteNewtonMassachusetts02459-
Alkermes Investigational SiteLansingMichigan48911-
Alkermes Investigational SiteCincinnatiOhio45245-
Alkermes Investigational SiteWyomissingPennsylvania19610-
Alkermes Investigational SiteColumbiaSouth Carolina29201-
Alkermes Investigational SiteAustinTexas78731-
Alkermes Investigational SiteSan AntonioTexas78229-
Alkermes Investigational SiteSugar LandTexas77478-

Find similar trials in Boulder, CO

Related Studies